Clavijo C, Chen J-L, Kim K-J, Reyland ME, Ann DK. Protein kinase C␦-dependent and -independent signaling in genotoxic response to treatment of desferroxamine, a hypoxia-mimetic agent. Am J Physiol Cell Physiol 292: C2150-C2160, 2007; doi:10.1152/ajpcell.00425.2006.-Protein kinase C (PKC) plays a critical role in diseases such as cancer, stroke, and cardiac ischemia and participates in a variety of signal transduction pathways including apoptosis, cell proliferation, and tumor suppression. Here, we demonstrate that PKC␦ is proteolytically cleaved and translocated to the nucleus in a time-dependent manner on treatment of desferroxamine (DFO), a hypoxia-mimetic agent. Specific knockdown of the endogenous PKC␦ by RNAi (sh-PKC␦) or expression of the kinase-dead (Lys376Arg) mutant of PKC␦ (PKC␦KD) conferred modulation on the cellular adaptive responses to DFO treatment. Notably, the time-dependent accumulation of DFOinduced phosphorylation of Ser-139-H2AX (␥-H2AX), a hallmark for DNA damage, was altered by sh-PKC␦, and sh-PKC␦ completely abrogated the activation of caspase-3 in DFO-treated cells. Expression of Lys376Arg-mutated PKC␦-enhanced green fluorescent protein (EGFP) appears to abrogate DFO/hypoxia-induced activation of endogenous PKC␦ and caspase-3, suggesting that PKC␦KD-EGFP serves a dominant-negative function. Additionally, DFO treatment also led to the activation of Chk1, p53, and Akt, where DFO-induced activation of p53, Chk1, and Akt occurred in both PKC␦-dependent and -independent manners. In summary, these findings suggest that the activation of a PKC␦-mediated signaling network is one of the critical contributing factors involved in fine-tuning of the DNA damage response to DFO treatment. DNA damage; caspase-3; Akt DESFERROXAMINE (DFO), an iron chelator, is known to regulate the expression of hypoxia-inducible genes, such as vascular endothelial growth factor, by stabilizing hypoxia-inducible factor-1␣ (HIF-1␣) (6, 35). Iron chelation also affects the activity of a number of enzymes, including those in the respiratory chain complexes, which require the formation of heme groups or iron-sulfur clusters. As a consequence, treatment with a subtoxic concentration of DFO leads to a reduction of total cellular ATP levels and a decrease in the proportion of cells with active mitochondria (52). Taking advantage of this hypoxia-mimicking effect, DFO treatment has been widely used as a method to experimentally simulate hypoxic conditions (22). Clinical trials have further confirmed a promising lead for DFO as a therapeutic agent against certain types of cancer (6, 8, 35) . Hypoxia-reoxygenation has been shown to cause DNA replication fork arrest, followed by DNA damage and stabilization of p53, resulting in the DNA damage response (18, 20) . The DNA damage response is usually initiated by the activation of the ataxia telangiectasia mutated (ATM) and the homologous ATM-and Rad3-related (ATR) proteins (46).
DNA damage; caspase-3; Akt DESFERROXAMINE (DFO), an iron chelator, is known to regulate the expression of hypoxia-inducible genes, such as vascular endothelial growth factor, by stabilizing hypoxia-inducible factor-1␣ (HIF-1␣) (6, 35) . Iron chelation also affects the activity of a number of enzymes, including those in the respiratory chain complexes, which require the formation of heme groups or iron-sulfur clusters. As a consequence, treatment with a subtoxic concentration of DFO leads to a reduction of total cellular ATP levels and a decrease in the proportion of cells with active mitochondria (52) . Taking advantage of this hypoxia-mimicking effect, DFO treatment has been widely used as a method to experimentally simulate hypoxic conditions (22) . Clinical trials have further confirmed a promising lead for DFO as a therapeutic agent against certain types of cancer (6, 8, 35) .
Hypoxia-reoxygenation has been shown to cause DNA replication fork arrest, followed by DNA damage and stabilization of p53, resulting in the DNA damage response (18, 20) . The DNA damage response is usually initiated by the activation of the ataxia telangiectasia mutated (ATM) and the homologous ATM-and Rad3-related (ATR) proteins (46) . ATM and ATR share many common substrates and are usually activated with distinct kinetics or by different genotoxins. Once activated, ATM phosphorylates various downstream substrates, including p53, Chkl, Chk2, and the histone H2AX. ATM activation exerts three crucial functions: regulation and stimulation of DNA repair, signaling of cell cycle checkpoints, and signaling of cell death (29) . If unrepaired, this DNA damage, especially DNA double-stranded breaks (DSBs), could trigger cell death. Caspases are intracellular cysteine proteases that mediate cell death and inflammation. Caspase-3 is a major mediator of apoptotic cell death (55) . Conversely, the protein Akt is a serine-threonine kinase that has a central role in provoking suppression of apoptosis. Inhibition of apoptosis by Akt leads to increased cell survival (1) . The substrates of Akt include proapoptotic Bad, caspase-9, and ASK1, leading to a direct suppression of the mitochondrial apoptotic pathway. Since DFO mimics the hypoxic condition in various cells and tissues, it will be of great interests to evaluate the effect of DFO treatment on modulating the DNA damage response and pro/ anti-apoptotic signaling and their cross talk.
The protein kinase C (PKC) family of serine-threonine kinases is activated by diverse stimuli and participates in a variety of cellular processes, such as growth, differentiation, apoptosis, and cellular senescence (2, 9, 19, 47, 51, 56) . To date, the PKC family comprises 11 isoforms that are subgrouped on the basis of structure and their activation modes into 3 subfamilies: the classical PKCs (-␣, -␤, and -␥), which are activated by diacylglycerol (DAG) and calcium; the novel PKCs (-␦, -⑀, -, and -), which require DAG, but not calcium, for activation; and the atypical PKCs (-and -/), which can be activated in a DAG-and calcium-independent manner (5, 40, 47) . Studies with PKC␦ Ϫ/Ϫ mice suggest that PKC␦ plays pivotal roles in the regulation of cell proliferation and apoptosis (2, 21, 30, 47) . Mechanistically, PKC␦ is activated in response to numerous cellular stimuli by various mechanisms, including membrane translocation (23, 49) , protein-protein interaction (3), tyrosine phosphorylation (11, 25) , and proteo-lytic cleavage (11, 25, 44) . The translocation of PKC␦ to different subcellular compartments and/or proteolytic cleavage can be induced by ceramide, TNF-␣, UV irradiation, ionizing radiation, testosterone, oxidative stress, and etoposide (5, 13, 37, 38, 44) .
Although PKC␦ plays a central role in the regulation of responses incurred by a variety of stimuli, a detailed characterization of the function of PKC␦ and its underlying mechanism under a hypoxia-or DFO-induced stress condition is still elusive. Herein, we report that PKC␦ is a key regulator of the salivary adaptive signaling network in response to the genotoxic stress elicited by DFO treatment. We used lentiviral delivery of sh-PKC␦, wildtype PKC␦-enhanced green fluorescent protein (EGFP), or Lys376Arg-mutated PKC␦-EGFP to investigate DFO-mediated PKC␦ activation and examine whether DNA damage and cell survival pathways are differentially regulated in salivary epithelial Pa-4 cells with a number of distinct PKC␦ contexts upon the exposure of cells to DFO. Results from our studies demonstrate a time-dependent proteolytic activation and nuclear translocation of PKC␦ in response to DFO treatment. We further establish that the Lys376 residue of PKC␦ is essential for DFO-induced PKC␦ activation, and that Lys376Arg-mutated PKC␦-EGFP functionally dysregulates PKC␦-dependent adaptive responses in a dominant-negative manner. Our results also suggest that DFO treatment induces differential p53, Chk1, and Akt activation profiles in Pa-4, Pa-4/sh-PKC␦, and Pa-4/PKC␦KD-EGFP cells. The latter results provide a potential underlying mechanism by which fine tuning of salivary cellular responses to genotoxic responses on treatment with DFO may be accomplished through PKC␦. A cross talk among the activated PKC␦, caspase-3, Akt, and ATM signaling pathways is proposed. To the best of our knowledge, this is the first demonstration showing that PKC␦ plays a unique role in mediating adaptive responses to DFO-exerted genotoxicity.
MATERIALS AND METHODS
Cell culture. The rat parotid epithelial Pa-4 cell line and all variants generated were cultured on Primaria culture dishes (Falcon) with Dulbecco's modified Eagle's/F-12 (DME/F-12, 1:1 mixture) medium supplemented with 2.4% fetal bovine serum, insulin (5 g/ml), L-glutamine (2.3 mM), transferrin (5 g/ml), epidermal growth factor (25 ng/ml), hydrocortisone (1.1 M), glutamate (5 mM), T 3 (3,3Ј,5-triiodo-L-thyronine) (1.7 nM), kanamycin (94 g/ml), and fungizone (47 g/ml) and maintained at 35°C in a humidified atmosphere of 5% CO 2 and 95% air (33, 43) .
Design and generation of lentiviral constructs. The lentilox 3.7 expression vector (pLL3.7) (45) was used as the frame for the generation of both gene silencing and overexpression vectors. For gene silencing, the EGFP encoding sequence was deleted from pLL3.7 by restriction enzyme digestion and compatible ends re-ligation, yielding the so-called gene silencing empty vector (pGS-EV). This empty vector was linearized by digestion with HpaI and XhoI restriction enzymes, and a preannealed synthetic short hairpin (sh) DNA fragment was directionally ligated. To facilitate the screening of positive clones, a BamHI restriction site was included in the sh sequence. The sequences of all sh constructs used in this study are summarized in Table 1 . Each construct was engineered downstream of the human U6 promoter in the pGS-EV. For overexpression or exogenous expression, the wildtype pPKC␦WT-EGFP and kinase-dead (KD; a Lys376Arg mutation in the ATP binding site) pPKC␦KD-EGFP (13) were subcloned downstream of the cytomegalovirus (CMV) promoter in pLL3.7 to generate lenti-PKC␦WT-EGFP and lenti-PKC␦KD-EGFP, respectively. As a negative control, the PKC␦WT-EGFP sequence was deleted by restriction enzyme digestion and compatible ends religated, yielding the so-called overexpression empty vector (pOE-EV). All constructs were verified by DNA sequencing.
Lentivirus-mediated transduction. Lentiviruses with the corresponding expression constructs were made as previously described (7) . Briefly, human 293T cells (80 -90% confluence) in T175 culture flasks were co-transfected by the calcium phosphate precipitation method with a total amount of 106 g of DNA distributed in equimolar quantities of the corresponding lenti-construct, pCMVdelta-8. 
Sh, short hairpin.
Transduction of Pa-4 cells.
For lentiviral infection, Pa-4 cells were plated 1 day before infection and cultured overnight to reach 25% confluence. The culture medium was then aspirated, and fresh medium containing concentrated virus was added and incubated for 24 h in the presence of polybrene (9 g/ml). With the use of fluorescenceactivated cell sorter (FACS) analyses to monitor EGFP expression, a dose-dependent transduction was established in Pa-4 cells by increasing the multiplicity of infection (MOI) from 0.1 to 40 to yield 21-99% EGFP-positive cells, respectively, as confirmed in part by immunofluorescence microscopy (data not shown).
Cloning and characterization of transduced cell lines derived from Pa-4 cells. Transduced Pa-4 cells were cloned by serial dilution to obtain single cell-derived clones. For gene silencing studies, clones expressing the lowest PKC␦ protein levels, based on Western analyses with an antibody against PKC␦, were used. For studies of kinase function of PKC␦, clones were initially screened for the overexpression of exogenous pPKC␦-EGFP chimeric constructs by fluorescence microscopy and then further confirmed by Western analyses using an antibody that detects GFP tag. Clones expressing the highest exogenous protein levels were then used. All cells used in this study are summarized in Table 2 .
Western analyses. Whole cell lysates were prepared by lysing cells with radioimmunoprecipitation (RIPA) buffer (25 mM Tris, 125 mM NaCl, 1% Nonidet-P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide, pH 8.0) plus Complete Protease Inhibitor Cocktail (Roche) containing 1 mM NaF and 2 mM Na 3VO4 and subjected to SDS-PAGE, followed by immunoblotting with antibod Live cell imaging. Pa-4/PKC␦WT-EGFP and Pa-4/PKC␦KD-EGFP cells were seeded at 25% confluence in eight-well cell culture chambers (Lab-Tek) and cultured for 24 h. Cells were then treated without or with 50 M DFO (time t ϭ 0), and images were acquired at 0, 12, 24, 36, and 48 h. Exposure time under UV light irradiation was kept as short as possible, and cells with no DFO treatment served as a control, using a Nikon epifluorescence inverted microscope. Five randomly selected fields per each specimen were acquired per time point with a total magnification of ϫ600. Acquired images were processed using Metamorph Imaging, Corel Photo-Paint, and LSM 5 Image Browser Software. For confocal images, cells were examined using a Nikon PCM 2000 Confocal System equipped with argon ion and green HeNe lasers attached to a Nikon TE300 Quantum inverted microscope (Center for Liver Disease Research, Univ. of Southern California).
Immunocytochemistry. Cells were seeded and treated as described for live cell images, except for using 16-well cell culture chambers (Lab-Tek), and further processed for immunofluorescence microscopy. Briefly, DFO-treated and control cells were rinsed with phosphate-buffered saline (PBS), fixed with 2% paraformaldehyde in PBS, quenched with 50 mM ammonium chloride in PBS, permeabilized with 0.5% Triton X-100 in PBS, blocked with 1% bovine serum albumin in PBS, and incubated with the corresponding primary antibody. Cells were then washed with PBS, followed by incubation with the corresponding secondary antibody to obtain multicolor staining. The secondary antibodies used were as follows: goat-anti-mouse antibody conjugated to fluorescein isothiocyanate (FITC; ICN Pharmaceuticals, Cappel Products) or conjugated to tetramethyl-rhodamine (TMR; Santa Cruz Biotechnologies) and goat-anti-rabbit antibody conjugated to TMR or FITC. 4'-6-Diamidine-2-phenyl indole (DAPI; Molecular Probes) was used as a counterstain for identification of nuclei.
MTT assays for measurement of cell viability. Pa-4, Pa-4/sh-PKC␦, Pa-4/PKC␦WT-EGFP, or Pa-4/PKC␦KD-EGFP cells were seeded into 24-well plates to reach 35-50% confluence on the day of the experiment. The cells were treated with 100 M DFO or vehicle for 48 h followed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma) assay according to the manufacturer's recommendations. Absorbance of each well was read at 540 nm in a scanning multiwell spectrophotometer. The results, depicted as percentage of cell viability, are reported as means Ϯ SD of three independent experiments performed in triplicate. P values from twosidedt-test were calculated, and the difference between two data sets is significant when P Ͻ 0.05.
Flow cytometry for cell cycle analyses. Pa-4, Pa-4/sh-PKC␦, or Pa-4/PKC␦KD-EGFP cells were seeded at 50 -80% confluence in 35-mm dishes and synchronized by serum starvation overnight. After treatment with 100 M DFO for different time points, as indicated, cells were fixed in 70% ethanol overnight and stained with propidium iodide (PI)-Triton X-100-RNase A in PBS for 30 min at room temperature. Flow cytometry was performed using FACSCaliber (Becton Dickinson) as previously described (41) . Statistical analyses were performed by two-way ANOVA, with randomized sample blocks and post hoc tests using Fisher's least-squared difference method of protected t-tests. P Ͻ 0.05 was considered statistically significant.
RESULTS

PKC␦ is proteolytically activated on DFO treatment.
To establish the role of PKC␦ in DFO-induced cellular response(s), we engineered a series of lentivirus constructs expressing wildtype (WT) or KD (Lys376Arg) PKC␦ fused to EGFP (PKC␦WT-EGFP or PKC␦KD-EGFP, respectively), or RNAi (sh-PKC␦) for suppressing the expression of endogenous PKC␦, as described in MATERIALS AND METHODS. Since salivary Pa-4 cells express a high level of endogenous PKC␦, they were chosen to be an experimental model for our studies to achieve our goal. Pools of Pa-4 cells transduced with individual lentivirus, harboring either PKC␦WT-EGFP or PKC␦KD-EGFP, were used to obtain clones of Pa-4/ PKC␦WT-EGFP or Pa-4/PKC␦KD-EGFP, respectively (Fig. 1A) . Individual clones, expressing the highest protein levels of PKC␦WT-EGFP or PKC␦KD-EGFP, were selected and expanded for use in the experiments reported herein. To downregulate PKC␦ expression, four different sh-PKC␦s were pooled in a simultaneous transduction to obtain ϳ40% PKC␦ gene silencing effect (Fig. 1A) . This pool of transduced cells was further used to obtain several individual clones. Two of these clones showed Ն90% downregulation of endogenous PKC␦ expression (Fig. 1A , clones 5 and 7) and were used for the studies shown herein. A summary of the engineered cell pools and cell lines used in this study is shown in Table 2 .
We next characterized whether DFO elicits PKC␦ activation. One reported mechanism underlying PKC␦ activation is its proteolytic cleavage, which yields a 40-kDa catalytic fragment (CF) with a constitutive kinase activity (12) . The generation of PKC␦-CF has been considered a hallmark of PKC␦ activation in apoptotic cells (13, 15, 17) . As demonstrated in (Fig. 1C, top) . Pa-4/sh-PKC␦ cells served as a control (Fig. 1C,  middle) to ascertain the validity of PKC␦-CF generation in Pa-4 cells in response to DFO treatment. Intriguingly, PKC␦KD-EGFP delayed the accumulation of PKC␦-CF from endogenous PKC␦ (Fig. 1C, bottom; 3.4-and 4.1-fold increase in Pa-4 cells vs. 1.7-and 2.3-fold in Pa-4/PKC␦KD cells at 32 and 40 h posttreatment, respectively), indicating that Lys376Arg mutation of PKC␦KD-EGFP affects the generation of PKC␦-CF from endogenous PKC␦ in DFO-treated cells. Conceivably, the kinase activity is perhaps required for an earlier event necessary for DFO-elicited PKC␦ cleavage in Pa-4 cells.
DFO stimulates nuclear translocation of PKC␦. The activation of classical and novel PKC is often noted with their translocation from the soluble to the particulate cellular fractions through the interaction between the C1 domain and membrane lipids (40) . Since subcellular localization change is expected on PKC␦ activation, we performed immunocytochemical analyses to investigate whether DFO treatment induces PKC␦ translocation to different cellular compartments. As shown in Fig. 2A , endogenous PKC␦ was seen throughout the cells before DFO treatment (Fig. 2Aa) . Following treatment with DFO, PKC␦ became enriched in the nucleus, where the intensity of signals detected from endogenous PKC␦ reached maximum between 24 and 32 h posttreatment ( Fig. 2A, b-d) , correlating with time-dependent generation of PKC␦-CF (Fig.  1C) . We next tried to confirm this observation by performing imaging analyses with Pa-4/PKC␦WT-EGFP cells through monitoring EGFP signals at different post-DFO treatment time points (Fig. 2B) . Notably, PKC␦WT-EGFP exhibited a restricted vesicle-like signal surrounding the nucleus in untreated cells (Fig. 2B, a and b) but translocated to the nucleus (Fig. 2B , j, n, and r, and Fig. 2Cc ) in DFO-treated cells. Although the gross intracellular localization of PKC␦ and the trend of nuclear translocation kinetics during the course of DFO treatment were comparable between the endogenous PKC␦ and the stably expressed PKC␦WT-EGFP, notable differences existed. We cannot, however, rule out the possibility that EGFP tagging perhaps contributes, at least in part, to the localization of PKC␦WT-EGFP fusion protein and the kinetics of PKC␦WT-EGFP nuclear translocation on DFO exposure (Fig. 2B ) compared with those seen with endogenous PKC␦ (Fig. 2A) .
On the other hand, these analyses also indicated that PKC␦KD-EGFP failed to locate in the nucleus of DFO-treated cells (Fig. 2B, t vs. r) . Instead, scanning confocal microscopy with analyses using reconstruction of orthogonal image planes indicated that PKC␦KD-EGFP was enriched at the plasma membrane at 48 h posttreatment (Fig. 2Cd) , suggesting that the Lys-to-Arg mutation of PKC␦ at amino acid residue 376 abolished its DFO-induced nuclear translocation capacity. Compared with PKC␦WT-EGFP signals, a substantial portion of PKC␦KD-EGFP signals were localized in a perinuclear compartment under the control condition, while DFO treatment enriched the perinuclear localization of PKC␦KD-EGFP (Fig. 2 , B and C). Although the exact mechanism underlying differential localization between PKC␦WT-EGFP and PKC␦KD-EGFP remains elusive, we surmise that transient recruitment of PKC␦ to a peripheral cellular location, probably the plasma membrane, is part of the PKC␦ sorting or activation process and that the Lys376Arg mutation renders PKC␦KD-EGFP sequestered at the plasma membrane.
Dysregulation of DFO-induced DNA damage response signaling by sh-PKC␦ or PKC␦KD-EGFP. DFO treatment has been reported, by us and others (10, 41) , to affect genome integrity. We next performed biochemical studies to investigate the cross talk between the ATM cascade and PKC␦ signaling during DFO-induced adaptive responses. We first evaluated the phosphorylation status of ATM and its substrate H2AX in Pa-4 cells treated with DFO for different time periods. ATM activation was assessed by ATM phosphorylation at Ser-1981 during the course of DFO treatment (Fig. 3A,  top) . Moreover, it is likely that manipulation of the PKC␦ level, by use of sh-PKC␦ or PKC␦ function by expression of PKC␦KD-EGFP, evoked a modest modulation of the fold-ofactivation or the onset of maximal induction, as noted by the quantitative analysis of the relative pSer-1981-ATM level in each sample (Fig. 3A, middle and bottom) .
In addition, H2AX, a hallmark of genotoxicity, was phosphorylated at Ser-139 (␥-H2AX), and ␥-H2AX signals accumulated with increasing periods of DFO exposure (Fig. 3A,  top) , which was further confirmed by immunocytochemical analyses (Fig. 3B, c and d) . There was an apparent localization of both ␥-H2AX and PKC␦ in the nucleus of DFO-treated cells (Fig. 3B, n-p) . We next examined whether PKC␦ is involved in DFO-elicited ␥-H2AX activation. As shown in Fig. 3A (middle) , the sustained high level of ␥-H2AX signals from 16 to 48 h post-DFO treatment in both Pa-4/sh-PKC␦ and Pa-4/ PKC␦KD-EGFP cells was lacking, suggesting that PKC␦ is not necessary for the initial ␥-H2AX phosphorylation but may be essential for the maintenance of high levels of ␥-H2AX. Using this data, together with the data from Fig. 2 , we surmised that PKC␦ contributes, at least in part, to the pathways leading to the activation of the DNA damage response in DFO-treated cells.
Phosphorylation of both p53 at Ser-15 and Chk1 at Ser-345 has also been shown to be involved in DNA damage signaling (36, 39, 50) . To determine whether different PKC␦ contexts affect DFO-induced activation of a molecule(s) other than ATM, we assessed the phosphorylation profile of p53 at Ser-15 (pSer15-p53) and Chk1 at Ser-345 (pSer345-Chk1) on exposure to DFO in parental and engineered Pa-4 cells. As shown in Fig. 3C , exposure to DFO caused a sustained induction of pSer15-p53 and a temporal increase of pSer345-Chk1 signal in all cells tested. Both the durations and signals of pSer345-Chk1 and pSer15-p53 were somehow altered in both DFO-treated Pa-4/sh-PKC␦ and Pa-4/PKC␦KD-EGFP cells. Taken together, these data demonstrate that it is likely that DNA damage signaling pathways other than ATM may also contribute to the DFO-mediated signaling events.
Activation of proapoptotic caspase-3 and prosurvival Akt in response to DFO treatment. Because caspase-3 is a key effector component of several apoptotic signaling pathways (4, 42, 48), we next explored the possibility that caspase-3 also participates in DFO/PKC␦-mediated signaling. The characteristic cleavage of caspase-3, a hallmark of caspase-3 activation, appeared to occur ϳ32 h post-DFO treatment (Fig. 4A, top) , correlating with PKC␦ cleavage (Fig. 1C) and ␥-H2AX activation (Fig. 3A) . Since PKC␦ has been implicated in a positive activation loop with caspase-3 in other apoptotic contexts (5), we also evaluated the effect of PKC␦ expression on DFOmediated caspase-3 activation. As expected, the steady-state levels of the cleaved fragment of caspase-3 (caspase-3-CF) in Pa-4/sh-PKC␦ and Pa-4/PKC␦KD-EGFP cells were barely detectable by Western analyses during the course of DFO treatment (Fig. 4A, two bottom panels) , suggesting that PKC␦ is necessary for DFO-induced caspase-3 activation.
As shown in Fig. 4B , we further evaluated the correlation between caspase-3 and DFO-induced activation of PKC␦ and DNA damage signaling in caspase-3-deficient MCF7/Neo and MCF7/Caspase-3 cells (24) . It is worth noting that DFO induced the appearance of PKC␦-CF only in MCF7/Caspase-3 and not in MCF7/Neo cells, suggesting that caspase-3 also participates in DFO-activated proteolytic cleavage of PKC␦. While DFO-triggered phosphorylation of p53 at Ser-15 was not affected by the absence of caspase-3 in MCF7 cells, the induction of Chk1 phosphorylation at Ser-345 was notably reduced in MCF7/Caspase-3 cells (Fig. 4B) . Together with data shown in Fig. 3C , these latter data led us to envisage the possibility that DFO treatment activates p53 and Chk1 using PKC␦/caspase-3-independent pathways. Next, we evaluated the effect of PKC␦ on the Akt activation profile during the DFO-induced responses. As shown in Fig.  4C , Ser-473-Akt was modestly phosphorylated by DFO treatment, while no marked difference in the profile of DFOinduced Ser-473-Akt phosphorylation was noticed throughout the time course we examined using the three cell lines. In some experiments, we observed that pSer-473-Akt was induced at ϳ8 h posttreatment with DFO, followed by downregulation of the pSer-473-Akt signal until approximately 40ϳ48 h posttreatment (Fig. 4C, top) context (Fig. 4C) . In a comparison of their DFO-induced pSer-473-Akt and pThr-308-Akt profiles (Fig. 4C ), PKC␦ appears to play a fine-tuning role in modulation of DFO-triggered Akt phosphorylation. Last, we examined whether we could extend our observations that PKC␦KD-EGFP attenuates the DFO-induced proteolytic activation of PKC␦ and caspase-3 in response to hypoxic exposure. As shown in Fig. 4D , it appeared that PKC␦KD-EGFP also modulated the generation of PKC␦-CF and caspase-3-CF on prolonged exposure to 1% O 2 (Fig. 4D, bottom) , supporting the notion that PKC␦ could play a vital role in modulating the cellular response to adverse conditions, such as exposure to DFO or 1% O 2 . However, 1% O 2 -evoked PKC␦-CF began to appear, at a significant level, 8 h earlier in Pa-4/ PKC␦KD-EGFP cells than in Pa-4 cells (Fig. 4D) . The exact reason underlying this phenomenon is still unclear.
The involvement of PKC␦ in DFO-induced cellular responses in Pa-4 cells.
To further evaluate the contribution of PKC␦ to DFO-mediated signaling cross talk and its biological consequences, these parental and engineered Pa-4 cells were assayed for their sensitivity toward DFO-mediated cell growth inhibition by MTT assays. As shown in Fig. 5A , both Pa-4 cells with decreased expression of endogenous PKC␦ and Pa-4 cells expressing PKC␦KD-EGFP were less sensitive to DFO treatment than parental Pa-4 cells, the pool of transduced cells with PKC␦WT-EGFP, and cells transfected with the corresponding empty vector (data not shown). These data support our notion that PKC␦ plays an antagonistic role by suppressing cell survival in response to DFO. The lack of further enhancement in DFO-elicited cell growth inhibition by exogenous PKC␦WT-EGFP suggests that the endogenous PKC␦ level in Pa-4 cells may be sufficient for conveying the signaling elicited by DFO, or a PKC␦-independent pathway may counter the effect of an enhanced PKC␦/caspase-3 pathway. Since DFO treatment is known to arrest Pa-4 cells in S-phase and induce apoptosis (41), we also determined the role of PKC␦ in DFOelicited cell cycle dysregulation. Neither sh-PKC␦ nor exogenous PKC␦KD-EGFP alone conveyed a marked effect on modulating cell cycle progression before DFO treatment (data not shown). In Fig. 5B , except for 24 h post-DFO exposure in Pa-4/PKC␦KD-EGFP cells, significant increases in sub-G 1 cell population were observed in DFO-treated cells compared with vehicle-treated cells in all three cell lines. Moreover, we also observed significant decreases in sub-G 1 cell population for both Pa-4/sh-PKC␦ and Pa-4/PKC␦KD-EGFP cells compared with Pa-4 cells at both 24 and 48 h post-DFO treatment (Fig.  5B) . We concluded that PKC␦ enhances the cytotoxic effect of DFO in Pa-4 cells.
In summary, our data provide evidence for signaling cross talk in DFO-treated Pa-4 cells and suggest that both PKC␦-dependent and -independent pathways functionally cooperate to mediate salivary adaptive responses against DFO, as de- Fig. 2 . Kinase activity is required for nuclear translocation of PKC␦ on DFO treatment. A: DFO induces nuclear translocation of PKC␦. Pa-4 cells were seeded on 16-well cell culture chambers, treated with 50 M DFO, and harvested at the indicated time points. Cells were processed for immunocytochemistry as indicated in MATERIALS AND METHODS. Immunostaining of endogenous PKC␦ (green), DAPI staining for identification of nuclei (blue), and immunostaining for tubulin (red) are shown. Images were acquired using a Nikon epifluorescence inverted microscope and processed using Metamorph Imaging, Corel Photo-Paint, and LSM 5 Image Browser Software. B and C: PKC␦ kinase function is required for its DFO-induced nuclear translocation. Pa-4/PKC␦WT-EGFP or Pa-4/PKC␦KD-EGFP cells were seeded in 8-well cell culture chambers and treated either with or without 50 M DFO in full culture medium. Live cell images were acquired (B) at the indicated time points using a Nikon epifluorescence inverted microscope and processed as in A. C: orthogonal image planes were reconstructed using C-Imaging, Corel Photo-Paint, and LSM 5 Image Browser Software. DFO treatment induces a translocation of PKC␦-EGFP from cytoplasm to nucleus, whereas PKC␦KD-EGFP accumulates at the plasma membrane. picted in Fig. 5C . We postulate that DFO-mediated PKC␦ activation is part of a central regulatory circuit that directs an integrated balance between caspase-3/Akt-activated signaling and DNA damage response.
DISCUSSION
Several lines of evidence provided herein support the notion that PKC␦ activation is involved in DFO-elicited signaling events. First, DFO treatment induces time-dependent nuclear translocation and proteolytic cleavage of PKC␦ and PKC␦-dependent caspase-3 activation (Figs. 1, 2, and 4, A and B) . Second, PKC␦ maintains the high level of sustained ␥-H2AX signal, a hallmark of DNA damage response, on exposure to DFO (Fig. 3A) . Third, the kinase-dead PKC␦-EGFP is capable of attenuating DFO/hypoxia-induced activation of endogenous PKC␦ and caspase-3 (Figs. 1C and 4, A and D) . In addition, PKC␦KD-EGFP fails to be translocated to the nucleus of DFO-treated cells (Fig. 2, B and C) even though it harbors PKC␦ bipartite nuclear localization signal, as reported by DeVries et al. (13) , consistent with the proposed dominantnegative role of PKC␦KD (34) . Last, sh-PKC␦ or PKC␦KD-EGFP conveys partial resistance to DFO-elicited cytotoxicity (Fig. 5, A and B) . We conclude that PKC␦ is an important component of the activated signaling pathway, consequent to DFO treatment. Furthermore, DFO treatment also induces Chk1 and p53 phosphorylation in a PKC␦-independent manner (Figs. 3C and 4B) .
Although the hypoxia-mimetic effect of DFO has been well documented, no direct link between DFO-mediated genotoxic stress and activation of a specific PKC isoform has been described to date. Our present work suggests that PKC␦ is involved in mediating DFO-induced genotoxic responses. First, we showed that DFO-induced accumulation of DNA damage marker ␥-H2AX is modulated by expression of sh-PKC␦ or Lys376Arg-mutated PKC␦-EGFP. Current thinking predicts that ATM is activated by DNA DSBs and recruits more ATM molecules as well as other repair proteins and sensors, such as MRN, 53BP1 and MDC1, to the DNA lesion (16) . Moreover, ␥-H2AX can also be activated by DNAdependent protein kinase (DNA-PK) and ATR in addition to ATM. While our present work suggests that PKC␦ activation effects a sustained DFO-elicited ␥-H2AX activation (Fig. 3, A  and B) , the exact molecular mechanism underlying this observation is still elusive. It is possible that H2AX serves as a direct kinase substrate of nucleus-translocated PKC␦, given that PKC␦ is translocated to the nucleus during DFO treatment ( Figs. 2A and 3B) . Second, PKC␦ is cleaved by a caspase-3-dependent mechanism to a 40-kDa PKC␦-CF, analogous to PKC␦ activation in cells treated with genotoxic DNA damaging agents (13, 15) , in DFO-treated cells (Figs. 1B and 4B ). Because a relatively higher level of caspase-3-CF was observed in Pa-4/PKC␦WT-EGFP cells treated with DFO for 48 h (Fig. 4A) , a feedforward pathway for PKC␦ and caspase-3 reciprocal activation (Fig. 5C ) is likely to exist in response to DFO treatment, consistent with previous reports in other apoptotic systems (26, 27, 31, 44) . Moreover, overexpression of PKC␦-CF has been shown to induce chromatin condensation and DNA fragmentation, supporting a role for PKC␦-CF in mediating cell response to genotoxic stress (17) . Last, studies by others have also shown that PKC␦ interacts with p53 DINP1 and p53, leading to p53 phosphorylation on exposure to genotoxicity (53) , and that PKC␦ mediates the cytotoxic effect of arsenate-induced cell death (32) . In addition, cells derived from PKC␦ Ϫ/Ϫ mice were shown to be defective in mitochondria- dependent apoptosis (21, 30) . These findings collectively support our proposition of a progenotoxic role of PKC␦ in DFOdependent signaling in salivary epithelial cells. Previous studies have reported that treatment of cells with DNA damaging agents is associated with translocation of PKC␦ to the nucleus (13, 54) . However, these studies also showed that etoposide elicits PKC␦ proteolytic cleavage and p53 phosphorylation via a rapid induction in salivary cells in vitro and in vivo (13, 21) . By contrast, our present results suggest that the induction of PKC␦ and caspase-3 proteolytic cleavage and p53 phosphorylation by DFO treatment occurs in a delayed manner. One possible explanation for this timedependent action in DFO-treated cells is that DFO, a membrane-impermeant iron chelator, is taken up primarily by fluidphase endocytosis, travels through various endosomes to late endosomes, and eventually accumulates in the lysosomal compartment (14, 28) . It is plausible to assume that the change in the extent of DFO-chelatable irons in extracellular milieu and cytoplasmic and other subcellular compartments and membrane destabilization of these organelles result in the activation of various signaling pathways, including PKC␦, caspase-3, ATM, p53 and Chk1, in a rather delayed manner. In addition, we have recently reported that hypoxia or DFO treatment leads to a transient activation of the small ubiquitin-like modifier (SUMO)ylation process, and that overexpression of SUMO-1 protects salivary Pa-4 cells against hypoxic injury (41) . It is conceivable that SUMOylation alters and/or delays the signaling event(s) activated by DFO treatment.
While PKC␦ plays a role in mediating cell response to DFO treatment, as shown herein, a signaling pathway other than PKC␦ also contributes in part to the effect of DFO in salivary cells. It appears that the PKC␦-independent signaling pathway is also activated by DFO treatment. For example, the activation of both Chk1 and p53 is also known to be part of genotoxic responses. As shown in Fig. 3C , the DFO-exerted Chk1 phosphorylation at Ser-345 and p53 phosphorylation at Ser-15 were noted in cells lacking a functional PKC␦ pathway, such as Pa-4/sh-PKC␦ and Pa-4/PKC␦KD-EGFP cells. DFO treatment also induced Chk1 and p53 activation without generating PKC␦-CF in MCF7/Neo cells (Fig. 4B) . Consistent with our results is a report by Humphries et al. (21) , who demonstrated the involvement of a signaling pathway other than PKC␦ in governing the steady-state level of p53 and its Ser-15 phosphorylation under genotoxic conditions in cells prepared from PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice. Previously, Gibson et al. (18) reported that hypoxia induces Chk2 activation in an ATMdependent manner (18) . Our results unequivocally showed that DFO not only activates ATM (and presumably its downstream Chk2) but also induces PKC␦-independent Chk1 stimulation. Although Chk1 functionally shares many substrates with Chk2, we suggest that Chk1 activation may represent an additional pathway to ascertain a proper adaptive response to DFOinduced genotoxic stress.
A complete picture of the signaling pathways and functions of PKC␦ in DFO-treated cells has yet to emerge. The presented studies expanded our understanding of PKC␦ biology as well as perhaps the role of PKC␦ in regulating a DFO-and maybe hypoxia-induced adaptive response. Taken together, our data suggest a role for the cross talk of PKC␦ and DNA damage response signaling pathways in DFO-mediated genotoxicity and also demonstrate that both PKC␦-dependent and -independent pathways functionally cooperate to mediate salivary adaptive responses against DFO (Fig. 5C ).
